Effectiveness of degradable polymer film in the management of severe or moderate intrauterine adhesions (PREG-2): a randomized, double-blind, multicenter, stratified, superiority trial.

IF 6.6 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Fertility and sterility Pub Date : 2024-12-01 Epub Date: 2024-07-22 DOI:10.1016/j.fertnstert.2024.07.020
Hervé Fernandez, Laura Miquel, Jérémy Sroussi, Steven Weyers, Meritxell Munmany, Xiping Luo, Petr Kovar, Yue Wang, Brunella Zizolfi, Anna Surbone, Victoire Delporte, Enrique Moratalla, Marine Sauvan, Gaetano Perrini, Long Sui, Michal Mara
{"title":"Effectiveness of degradable polymer film in the management of severe or moderate intrauterine adhesions (PREG-2): a randomized, double-blind, multicenter, stratified, superiority trial.","authors":"Hervé Fernandez, Laura Miquel, Jérémy Sroussi, Steven Weyers, Meritxell Munmany, Xiping Luo, Petr Kovar, Yue Wang, Brunella Zizolfi, Anna Surbone, Victoire Delporte, Enrique Moratalla, Marine Sauvan, Gaetano Perrini, Long Sui, Michal Mara","doi":"10.1016/j.fertnstert.2024.07.020","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To study the effectiveness of a new intrauterine degradable polymer film (Womed Leaf) in the management of moderate to severe intrauterine adhesions (IUA).</p><p><strong>Design: </strong>PREG-2 study was a multicenter, double-blind, randomized, controlled, stratified, two-arm superiority clinical trial conducted in 16 centers in seven countries.</p><p><strong>Setting: </strong>Not applicable.</p><p><strong>Patient(s): </strong>Patients ≥18 years scheduled for hysteroscopic adhesiolysis because of symptomatic severe or moderate adhesions (according to American Fertility Society [AFS] IUA score) were considered eligible for the study.</p><p><strong>Intervention(s): </strong>After adhesiolysis, patients were randomized at a 1:1 ratio to either have a Womed Leaf film inserted (intervention group) or not (control group).</p><p><strong>Main outcome measure(s): </strong>The primary effectiveness endpoint of the study was the change in AFS IUA score on second-look hysteroscopy (SLH), assessed by an independent evaluator, and compared with baseline. Information on the rate of no IUA and responder rate was collected as secondary effectiveness outcomes, while reported adverse events and patient-reported outcomes as safety and tolerability measures.</p><p><strong>Result(s): </strong>Between October 26, 2021, and September 28, 2023, a total of 160 women were randomized (Womed Leaf: n = 75 and controls: n = 85). The reduction in IUA AFS score on SLH was significantly higher in the intervention compared with the control group (mean 5.2 ± 2.8 vs. 4.2 ± 3.2). Similarly, the absence of adhesions on SLH was significantly higher in the intervention group (41% vs. 24%; odds ratio, 2.44; confidence interval, 1.161-5.116). None of the reported adverse events were serious or considered related to the device.</p><p><strong>Conclusion(s): </strong>Womed Leaf is effective and safe in the management of symptomatic severe or moderate IUAs.</p><p><strong>Clinical trial registration number: </strong>Clinicaltrials.gov identifier: NCT04963179.</p>","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":" ","pages":"1124-1133"},"PeriodicalIF":6.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fertility and sterility","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.fertnstert.2024.07.020","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To study the effectiveness of a new intrauterine degradable polymer film (Womed Leaf) in the management of moderate to severe intrauterine adhesions (IUA).

Design: PREG-2 study was a multicenter, double-blind, randomized, controlled, stratified, two-arm superiority clinical trial conducted in 16 centers in seven countries.

Setting: Not applicable.

Patient(s): Patients ≥18 years scheduled for hysteroscopic adhesiolysis because of symptomatic severe or moderate adhesions (according to American Fertility Society [AFS] IUA score) were considered eligible for the study.

Intervention(s): After adhesiolysis, patients were randomized at a 1:1 ratio to either have a Womed Leaf film inserted (intervention group) or not (control group).

Main outcome measure(s): The primary effectiveness endpoint of the study was the change in AFS IUA score on second-look hysteroscopy (SLH), assessed by an independent evaluator, and compared with baseline. Information on the rate of no IUA and responder rate was collected as secondary effectiveness outcomes, while reported adverse events and patient-reported outcomes as safety and tolerability measures.

Result(s): Between October 26, 2021, and September 28, 2023, a total of 160 women were randomized (Womed Leaf: n = 75 and controls: n = 85). The reduction in IUA AFS score on SLH was significantly higher in the intervention compared with the control group (mean 5.2 ± 2.8 vs. 4.2 ± 3.2). Similarly, the absence of adhesions on SLH was significantly higher in the intervention group (41% vs. 24%; odds ratio, 2.44; confidence interval, 1.161-5.116). None of the reported adverse events were serious or considered related to the device.

Conclusion(s): Womed Leaf is effective and safe in the management of symptomatic severe or moderate IUAs.

Clinical trial registration number: Clinicaltrials.gov identifier: NCT04963179.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
可降解聚合物薄膜治疗重度或中度宫腔粘连的效果(PREG-2):随机、双盲、多中心、分层、优越性试验。
目的研究新型宫内可降解聚合物薄膜(Womed Leaf®)治疗中重度 IUA 的有效性:PREG2研究是一项多中心、双盲、随机对照、分层、双臂优效临床试验,在7个国家的16个中心进行:因无症状性重度或中度粘连(根据美国生育协会(AFS)IUA评分)而计划接受宫腔镜粘连溶解术的≥18岁患者均符合研究条件:干预措施:宫腔粘连切除术后,患者按1:1的比例随机选择植入沃美德叶片(干预组)或不植入沃美德叶片(对照组):研究的主要疗效终点是二诊宫腔镜检查(SLH)中 AFS IUA 评分与基线相比的变化,由独立评估员进行评估。收集无 IUA 率和应答率信息作为次要疗效指标,报告的不良事件和患者报告的结果作为安全性和耐受性指标:2021年10月26日至2023年9月28日期间,共有160名妇女接受了随机治疗(沃美叶:75人,对照组:85人)。与对照组相比,干预组在SLH上的IUA AFS评分降低幅度明显更高(平均值为5.2 ± 2.8 vs. 4.2 ± 3.2;P=0.0153)。同样,干预组在SLH检查中无粘连的比例也明显高于对照组(41% vs 24% OR 2.44 [CI 1.161 - 5.116]; p=0.0189)。报告的不良事件均不严重,也不认为与设备有关:结论:Womed Leaf 能有效、安全地治疗无症状的重度或中度宫腔粘连。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Fertility and sterility
Fertility and sterility 医学-妇产科学
CiteScore
11.30
自引率
6.00%
发文量
1446
审稿时长
31 days
期刊介绍: Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.
期刊最新文献
Preimplantation Genetic Testing post-Dobbs: REI Physician Perceptions of Impact on Counseling and Patient Decision Making. Childhood adversity and doctor visits in gynaecology: to screen or not to screen. Low doses of alkylating agents do not harm human ovarian tissue destined for cryopreservation. Preconception Chlamydia trachomatis seropositivity and fecundability, live birth, and adverse pregnancy outcomes. (Not) My body, my choice?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1